Latest news with #MettlerToledo
Yahoo
07-08-2025
- Business
- Yahoo
Sotera Health Company (SHC) Q2 Earnings: What To Expect
Healthcare services company Sotera Health (NASDAQ:) will be reporting results this Friday before market open. Here's what to expect. Sotera Health Company beat analysts' revenue expectations by 3.1% last quarter, reporting revenues of $254.5 million, up 2.6% year on year. It was a strong quarter for the company, with a solid beat of analysts' organic revenue estimates and a solid beat of analysts' EPS estimates. Is Sotera Health Company a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Sotera Health Company's revenue to be flat year on year at $275.6 million, slowing from the 8.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sotera Health Company has missed Wall Street's revenue estimates twice over the last two years. Looking at Sotera Health Company's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts' expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%. Read our full analysis of Mettler-Toledo's results here and Thermo Fisher's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.7% on average over the last month. Sotera Health Company is down 4.6% during the same time and is heading into earnings with an average analyst price target of $14.58 (compared to the current share price of $11.06). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
05-08-2025
- Business
- Yahoo
Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow
Life sciences company Bio-Techne (NASDAQ:TECH) will be reporting results this Wednesday before market open. Here's what investors should know. Bio-Techne met analysts' revenue expectations last quarter, reporting revenues of $316.2 million, up 4.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates. Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bio-Techne's revenue to grow 2.9% year on year to $314.9 million, improving from the 1.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street's revenue estimates five times over the last two years. Looking at Bio-Techne's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts' expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%. Read our full analysis of Mettler-Toledo's results here and Thermo Fisher's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Bio-Techne is up 6.3% during the same time and is heading into earnings with an average analyst price target of $66.50 (compared to the current share price of $54.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
04-08-2025
- Business
- Globe and Mail
Pablo Perversi to Join METTLER TOLEDO Board of Directors
Mettler-Toledo International Inc. (NYSE: MTD) announced today that Pablo Perversi has been appointed to its Board of Directors, effective November 6, 2025. Mr. Perversi is the President of Europe at Danone, a leading global food and beverage company, and a member of its Executive Committee. Prior to his current role, Pablo served as Chief Innovation, Quality, and Sustainability Officer and President of Gourmet Division for Barry Callebaut from 2017 to 2022. Before that, he held various roles of increasing responsibility at Unilever from 1993 to 2017, his last position there being Vice President of Foods Europe. Roland Diggelmann, Chair of the Board, stated, 'Pablo is a very accomplished leader of global organizations in the food industry, an important market for METTLER TOLEDO. His wealth of experience from over 30 years of leadership at branded food companies across Europe, Latin America, and Asia will provide valuable perspectives to our business. We welcome Pablo and look forward to his contributions to our Board.' METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit
Yahoo
03-08-2025
- Business
- Yahoo
Earnings To Watch: Bruker (BRKR) Reports Q2 Results Tomorrow
Scientific instrument company Bruker (NASDAQ:BRKR). will be reporting earnings this Monday before market open. Here's what you need to know. Bruker beat analysts' revenue expectations by 4.3% last quarter, reporting revenues of $801.4 million, up 11% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' organic revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Is Bruker a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bruker's revenue to grow 1.1% year on year to $809.2 million, slowing from the 17.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share. Heading into earnings, analysts covering the company have mixed opinions about the business, with revenue estimates seeing 3 upward and 4 downward revisions over the last 30 days. Bruker has missed Wall Street's revenue estimates four times over the last two years. Looking at Bruker's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts' expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%. Read our full analysis of Mettler-Toledo's results here and Thermo Fisher's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Bruker is down 6.1% during the same time and is heading into earnings with an average analyst price target of $54.82 (compared to the current share price of $38.74). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-08-2025
- Business
- Yahoo
Waters Corporation (WAT) Reports Earnings Tomorrow: What To Expect
Scientific instruments company Waters Corporation (NYSE:WAT) will be reporting earnings this Monday before market hours. Here's what to look for. Waters Corporation beat analysts' revenue expectations by 1.2% last quarter, reporting revenues of $661.7 million, up 3.9% year on year. It was a satisfactory quarter for the company, with a narrow beat of analysts' organic revenue estimates. Is Waters Corporation a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Waters Corporation's revenue to grow 5.4% year on year to $746.6 million, a reversal from the 4.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.94 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Waters Corporation has missed Wall Street's revenue estimates twice over the last two years. Looking at Waters Corporation's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts' expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%. Read our full analysis of Mettler-Toledo's results here and Thermo Fisher's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Waters Corporation is down 16.3% during the same time and is heading into earnings with an average analyst price target of $373.98 (compared to the current share price of $290.31). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
